Memantine 10 mg
Memantine Hydrochloride Tablet, Coated
Product Images NDC 62332-076
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 62332-076). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Memantine 5 mg
Figure 1 (Memantine Fig1)
The text describes a figure labeled as "Figure 1" that shows the time course of the change from baseline in ADCS-ADL score for patients who completed 28 weeks of treatment with Memantine hydrochloride. The figure presents a mean score (+SEM) range from baseline and reports clinical improvement and decline.*
Figure 2 (Memantine Fig2)
The text describes a figure labeled as "Figure 2", which shows the cumulative percentage of patients who completed 28 weeks of double-blind treatment and their changes from baseline in ADCS-ADL scores. The figure has a vertical axis showing percentages and a horizontal axis showing score changes from baseline (ranging from -10 to 30). The text does not provide further context or information.*
Figure 4 (Memantine Fig4)
This is a graph, named "Figure 4", that displays the percentage of patients who completed a 28-week double-blind treatment and the changes from baseline in SIB (Severe Impairment Battery) scores. The treatment is related to placebo and memantine hydrochloride.*
Figure 6 (Memantine Fig6)
Figure 7 (Memantine Fig7)
Figure 8 (Memantine Fig8)
This is a figure showing the cumulative percentage of patients who completed 24 weeks of double-blind treatment with specified changes from baseline in SIB scores, using Donepezil and Memantine hydrochloride.*
Figure 3 (Memantine Figure3)
The text describes a figure displaying the time course of change in SIB score for patients who completed 28 weeks of treatment. The figure shows the mean change from baseline using the drug memantine hydrochloride. There is no additional information available in the given text.*
Figure 5 (Memantine Figure5)
The text describes a figure labeled as "Figure 5" that presents a graph showing the time course of change from baseline in ADCS-ADL score for patients who underwent 24 weeks of treatment. The mean and SEM are also provided in the figure. The text does not provide any further context or details, making it difficult to understand the purpose or results of the study.*
Memantine Str
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
